Hwang, M.D. is a pediatric neuro -oncologist and Di rector of the Pediatric Neuro -Oncology Fellowship Program at Children’s National Medical Center. Dr. Hwang received his pediatric neuro - oncology fellowship training at Duke University and worked with Dr. Mitchell during the development of the Re - MATCH pro tocol. He has a strong interest in pediatric immunotherapy and is collaborating with Dr. Mitchell on Re-MATC H Protocol Page 100 of 106 Version: 20180628 novel initiatives within the Pediatric Brain Tumor Consortium. Dr. Hwang will play an active role in the care of patients enrolled on this protocol and i n the integration of the Re -MATCH protocol with the outstanding clinical research team at CNMC. He will also oversee the collection and transport of leukapheresis products to the GMP facility at University of Florida for vaccine and T cell preparation and be directly responsible for vaccine administration for subjects enrolled at CNMC. http://www.childrensnational.org/findadoctor/profiles/eugene -hwang -4385.aspx CHILDREN’S HOSPITAL LOS ANGELES 4650 SUNSET BLVD LOS ANGELES, CA 90027 http://www.chla.org Girish Dhall, M.D. is Clinical Director of Neuro -Oncology at Children’s Hospital Los Angeles. He is an experienced pediatric hematology/oncologist who will oversee the management of subjects enrolled on the protocol at CHLA. Dr. Dhall will also direct the collection and dissemination of leukapheresis products for vaccine and T cell preparation to the University of Florida and the administration of vaccine products to subjects enrolled at CHLA. http://www.chla.org/site/apps/kb/ cs/contactdisplay.asp?c=ipINKTOAJsG&b=3832751&sid=ewJXIjPWJfLYKd P1KzG&r=1 Mark Krieger, M.D. is Division Chief of Pediatric Neurosurgery and Director of the Neurosurgery Fellowship Program at CHLA. Dr. Krieger is a highly -experienced pediatric neurosurgeon at one of the top ranked pediatric hospitals in the nation. He will oversee the protocol compliant collection and dissemination of tumor materials suitable for vaccine preparation at the CHLA site and in his duties as Division Chief will ensure the proper pre - and post operative management of subjects enrolled on this protocol. Dr. Krieger will also ensure coordination of information with the Neurosurgical Chair of the protocol, Dr. Gerald Grant at Stanford University. http://www.chla.org/site/apps/kb/cs/contactdisplay.asp?c=ipINKTOAJsG&b=3832751&sid=dvKTKhPVIiI5If MQJrF&r=1 25.2 Investigator Leadership Plan Drs. Mitchell, Grant, and Gururangan have been collaborators on several initiatives in experimental therapeutics for pediatric brain tumors for more than a year now, and are co- investigators on a grant award from the Pediatric Brain Tumor Foundation of the United States that has pr ovided support during the preclinical phases of this investigation and clinical trial planning period. The se individuals have jointly developed the experimental strategy prop osed in this application. This existing infrastructure and high -level expertise w ill be leveraged to integrate the novel immunotherapeutic platform that is the focus of this investigation. Drs. Grant and Gururangan have in the past and will continue to jointly oversee the surgical and post -surgical clinical care of the patients enroll ed on this protocol. This protocol will be carried out under an existing FDA -approved IND for use of amplified total tumor RNA loaded DCs in patients with malignant brain tumors (FDA IND -BB-14058) using standardized SOPs developed within Dr. Mitchell’s lab oratory that are centralized within the UF BTIP.